Notably, mutations in the RHO pathway genes are typically found at low prevalence in cancer genomes (Bustelo, 2018; Zandvakili et al., 2017; Svensmark and Brakebusch, 2019; Porter et al., 2016), suggesting that altered expression levels or aberrant activation by upstream oncogenic signals may constitute their predominant mode of contribution to tumorigenesis. This evidence concerns the gene RHO and cancer.